HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Senate Committee Restores FDA Funding For FY ’12

This article was originally published in The Tan Sheet

Executive Summary

The Senate Appropriations Committee gives FDA a boost for fiscal 2012 that likely will stick, thanks to the recent debt ceiling compromise.

You may also be interested in...

In Brief

Move Free, MegaRed extensions lift Schiff

House FDA Budget Bill Boosts User Fees, Trims Direct Appropriations

A House Appropriations subcommittee recommends cutting FDA's fiscal 2012 direct appropriations 11.5% while increasing user fees nearly 25%.

FDA Gets Boost In Fiscal 2011 Compromise, Cuts Loom For 2012

FDA is spared from the worst spending cuts for the remainder of fiscal 2011, but congressional Democrats warn of the potential for deep cuts ahead.


Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts